These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17692742)

  • 1. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure.
    Chan AK; Sanderson JE; Wang T; Lam W; Yip G; Wang M; Lam YY; Zhang Y; Yeung L; Wu EB; Chan WW; Wong JT; So N; Yu CM
    J Am Coll Cardiol; 2007 Aug; 50(7):591-6. PubMed ID: 17692742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.
    Kasama S; Toyama T; Sumino H; Matsumoto N; Sato Y; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
    J Nucl Med; 2007 Dec; 48(12):1993-2000. PubMed ID: 18006623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.
    White M; Rouleau JL; Afzal R; Floras J; Yusuf S; McKelvie RS
    Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):113-21. PubMed ID: 19299427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients.
    Orea-Tejeda A; Colín-Ramírez E; Castillo-Martínez L; Asensio-Lafuente E; Corzo-León D; González-Toledo R; Rebollar-González V; Narváez-David R; Dorantes-García J
    Rev Invest Clin; 2007; 59(2):103-7. PubMed ID: 17633796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction].
    Yoshiyama M; Omura T; Yoshikawa J
    Nihon Yakurigaku Zasshi; 2004 Aug; 124(2):83-9. PubMed ID: 15277726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis.
    Dahl JS; Videbaek L; Poulsen MK; Pellikka PA; Veien K; Andersen LI; Haghfelt T; Møller JE
    Am J Cardiol; 2010 Sep; 106(5):713-9. PubMed ID: 20723651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy].
    Skvortsov AA; Mareev VY; Chelmakina SM; Baklanova NA; Belenkov IuN
    Kardiologiia; 2007; 47(10):12-23. PubMed ID: 18260939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
    Fraccarollo D; Galuppo P; Schmidt I; Ertl G; Bauersachs J
    Cardiovasc Res; 2005 Jul; 67(1):97-105. PubMed ID: 15949473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.
    Edwards NC; Steeds RP; Stewart PM; Ferro CJ; Townend JN
    J Am Coll Cardiol; 2009 Aug; 54(6):505-12. PubMed ID: 19643310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does spironolactone have a dose-dependent effect on left ventricular remodeling in patients with preserved left ventricular function after an acute myocardial infarction?
    Vatankulu MA; Bacaksiz A; Sonmez O; Alihanoglu Y; Koc F; Demir K; Gul EE; Turfan M; Tasal A; Kayrak M; Yazici M; Ozdemir K
    Cardiovasc Ther; 2013 Aug; 31(4):224-9. PubMed ID: 22963506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
    Taniguchi I; Kawai M; Date T; Yoshida S; Seki S; Taniguchi M; Shimizu M; Mochizuki S
    Circ J; 2006 Aug; 70(8):995-1000. PubMed ID: 16864931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial structural effects of aldosterone receptor antagonism in heart failure.
    Cohn JN
    J Am Coll Cardiol; 2007 Aug; 50(7):597-9. PubMed ID: 17692743
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure.
    Vizzardi E; D'Aloia A; Giubbini R; Bordonali T; Bugatti S; Pezzali N; Romeo A; Dei Cas A; Metra M; Dei Cas L
    Am J Cardiol; 2010 Nov; 106(9):1292-6. PubMed ID: 21029826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure).
    Boccanelli A; Cacciatore G; Mureddu GF; de Simone G; Clemenza F; De Maria R; Di Lenarda A; Gavazzi A; Latini R; Masson S; Porcu M; Vanasia M; Gonzini L; Maggioni AP
    J Cardiovasc Med (Hagerstown); 2007 Sep; 8(9):683-91. PubMed ID: 17700397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.
    Colucci WS; Kolias TJ; Adams KF; Armstrong WF; Ghali JK; Gottlieb SS; Greenberg B; Klibaner MI; Kukin ML; Sugg JE;
    Circulation; 2007 Jul; 116(1):49-56. PubMed ID: 17576868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of spironolactone alone and in addition to a β-blocker on myocardial histological and electrical remodeling in chronic severe failing rat hearts.
    Milliez P; Gomes S; Champ-Rigot L; Callebert J; Samuel JL; Delcayre C
    J Cardiovasc Pharmacol; 2012 Sep; 60(3):315-21. PubMed ID: 22710814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.